These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 18784438)

  • 1. CA 19-9 response as an early indicator of the effectiveness of gemcitabine in patients with advanced pancreatic cancer.
    Nakai Y; Kawabe T; Isayama H; Sasaki T; Yagioka H; Yashima Y; Kogure H; Arizumi T; Togawa O; Ito Y; Matsubara S; Hirano K; Sasahira N; Tsujino T; Tada M; Omata M
    Oncology; 2008; 75(1-2):120-6. PubMed ID: 18784438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CA 19-9 as a biomarker in advanced pancreatic cancer patients randomised to gemcitabine plus axitinib or gemcitabine alone.
    Wasan HS; Springett GM; Chodkiewicz C; Wong R; Maurel J; Barone C; Rosbrook B; Ricart AD; Kim S; Spano JP
    Br J Cancer; 2009 Oct; 101(7):1162-7. PubMed ID: 19724276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decrease of CA 19-9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer.
    Halm U; Schumann T; Schiefke I; Witzigmann H; Mössner J; Keim V
    Br J Cancer; 2000 Mar; 82(5):1013-6. PubMed ID: 10737382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Irinotecan plus gemcitabine induces both radiographic and CA 19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer.
    Rocha Lima CM; Savarese D; Bruckner H; Dudek A; Eckardt J; Hainsworth J; Yunus F; Lester E; Miller W; Saville W; Elfring GL; Locker PK; Compton LD; Miller LL; Green MR
    J Clin Oncol; 2002 Mar; 20(5):1182-91. PubMed ID: 11870159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic factors and prognostic index for chemonaïve and gemcitabine-refractory patients with advanced pancreatic cancer.
    Maréchal R; Demols A; Gay F; De Maertelaere V; Arvanitaki M; Hendlisz A; Van Laethem JL
    Oncology; 2007; 73(1-2):41-51. PubMed ID: 18334830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial.
    Hess V; Glimelius B; Grawe P; Dietrich D; Bodoky G; Ruhstaller T; Bajetta E; Saletti P; Figer A; Scheithauer W; Herrmann R
    Lancet Oncol; 2008 Feb; 9(2):132-8. PubMed ID: 18249033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early decrement of serum carbohydrate antigen 19-9 predicts favorable outcome in advanced pancreatic cancer.
    Chung KH; Ryu JK; Lee BS; Jang DK; Lee SH; Kim YT
    J Gastroenterol Hepatol; 2016 Feb; 31(2):506-12. PubMed ID: 26250642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine.
    Ziske C; Schlie C; Gorschlüter M; Glasmacher A; Mey U; Strehl J; Sauerbruch T; Schmidt-Wolf IG
    Br J Cancer; 2003 Oct; 89(8):1413-7. PubMed ID: 14562009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of serum CA19-9 in patients with advanced pancreatic cancer receiving gemcitabine based chemotherapy.
    An X; Li YH; Lin XB; Wang FH; Feng F; Xu RH; Jiang WQ; He YJ
    Ai Zheng; 2009 Mar; 28(3):286-91. PubMed ID: 19619444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Are serial CA 19-9 kinetics helpful in predicting survival in patients with advanced or metastatic pancreatic cancer treated with gemcitabine and cisplatin?
    Stemmler J; Stieber P; Szymala AM; Schalhorn A; Schermuly MM; Wilkowski R; Helmberger T; Lamerz R; Stoffregen C; Niebler K; Garbrecht M; Heinemann V
    Onkologie; 2003 Oct; 26(5):462-7. PubMed ID: 14605463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pretreatment CA 19-9 level as a prognostic factor in patients with advanced pancreatic cancer treated with gemcitabine.
    Saad ED; Machado MC; Wajsbrot D; Abramoff R; Hoff PM; Tabacof J; Katz A; Simon SD; Gansl RC
    Int J Gastrointest Cancer; 2002; 32(1):35-41. PubMed ID: 12630768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prognostic significance of CA19-9 levels in patients with pancreatic cancer].
    Shiozawa S; Tsuchiya A; Kim DH; Ogawa K
    Nihon Rinsho; 2006 Jan; 64 Suppl 1():297-300. PubMed ID: 16457270
    [No Abstract]   [Full Text] [Related]  

  • 13. Second-line therapy for gemcitabine-pretreated advanced or metastatic pancreatic cancer.
    Altwegg R; Ychou M; Guillaumon V; Thezenas S; Senesse P; Flori N; Mazard T; Caillo L; Faure S; Samalin E; Assenat E
    World J Gastroenterol; 2012 Mar; 18(12):1357-64. PubMed ID: 22493549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prognostic factors in patients with advanced pancreatic cancer treated with gemcitabine chemotherapy: clinical characteristics of long-term survivors].
    An SG; Kim DU; Song GA; Jang AL
    Korean J Gastroenterol; 2014 Dec; 64(6):356-63. PubMed ID: 25530587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacogenomic study of gemcitabine efficacy in patients with metastatic pancreatic cancer: A multicenter, prospective, observational cohort study (GENESECT study).
    Hatori M; Tsuji D; Suzuki K; Yokokawa T; Kawakami K; Moriyama R; Osada-Tsuchiya M; Otake A; Nakao M; Yano T; Arakawa Y; Matsuo K; Ohashi Y; Sakata Y; Kogure Y; Tamaki S; Wada A; Taki Y; Sasahira N; Ishii H; Yamaguchi M; Itoh K
    Cancer; 2024 Sep; 130(17):2988-2999. PubMed ID: 38682652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of altered N-glycosylation of circulating glycoproteins in patients with unresectable pancreatic cancer treated with gemcitabine.
    Miyahara K; Nouso K; Morimoto Y; Kinugasa H; Kato H; Yamamoto N; Tsutsumi K; Kuwaki K; Onishi H; Ikeda F; Nakamura S; Shiraha H; Takaki A; Nakahara T; Miura Y; Asada H; Amano M; Nishimura S; Yamamoto K
    Pancreas; 2015 May; 44(4):551-6. PubMed ID: 25875794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical features of long time survivors with unresectable pancreatic cancer treated by gemcitabine alone].
    Kobayashi N; Fujita K; Fujisawa T; Takahashi H; Fujisawa N; Yoneda M; Abe Y; Inamori M; Kawamura H; Kirikoshi H; Shimamura T; Kubota K; Sakaguchi T; Saito S; Nakajima A
    Gan To Kagaku Ryoho; 2006 Feb; 33(2):207-12. PubMed ID: 16484857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CA19-9 as a predictor of tumor response and survival in patients with advanced pancreatic cancer treated with gemcitabine based chemotherapy.
    Hammad N; Heilbrun LK; Philip PA; Shields AF; Zalupski MM; Venkatramanamoorthy R; El-Rayes BF
    Asia Pac J Clin Oncol; 2010 Jun; 6(2):98-105. PubMed ID: 20565421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate.
    Rocha Lima CM; Green MR; Rotche R; Miller WH; Jeffrey GM; Cisar LA; Morganti A; Orlando N; Gruia G; Miller LL
    J Clin Oncol; 2004 Sep; 22(18):3776-83. PubMed ID: 15365074
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Full-dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pancreatic cancer: a multicenter phase II trial.
    Small W; Berlin J; Freedman GM; Lawrence T; Talamonti MS; Mulcahy MF; Chakravarthy AB; Konski AA; Zalupski MM; Philip PA; Kinsella TJ; Merchant NB; Hoffman JP; Benson AB; Nicol S; Xu RM; Gill JF; McGinn CJ
    J Clin Oncol; 2008 Feb; 26(6):942-7. PubMed ID: 18281668
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.